Keywords: Pfizer, sutent, prostate cancer, pipeline, roche, tarceva
Pfizer calls a halt to Phase III study of Sutent in prostate cancer
Article | 28 September 2010
Pfizer has discontinued a Phase III clinical trial of its Sutent (sunitinib malate) product in advanced castration-resistant prostate cancer after ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
